DHEA: why, when, and how much - DHEA replacement in adrenal insufficiency

被引:18
作者
Allolio, B.
Arlt, W.
Hahner, S.
机构
[1] Univ Wurzburg, Dept Med 1, Endocrinol & Diabet Unit, D-97080 Wurzburg, Germany
[2] Univ Birmingham, Sch Med, Div Med Sci, Birmingham B29 7EX, W Midlands, England
基金
英国医学研究理事会;
关键词
DHEA; adrenal insufficiency; DHEA replacement;
D O I
10.1016/j.ando.2007.06.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In recent years it has been demonstrated that current replacement therapy with glucocorticoids and mineralocorticoids fails to fully restore health-related quality of life in patients with adrenal insufficiency (Al). Accordingly, replacement of zona reticularis function by DHEA is of considerable interest. Available studies have demonstrated beneficial effects of DHEA on health perception, vitality, fatigue, and (in women) sexuality. DHEA restores low circulating androgens in women into the normal range and increases lGF-1 levels. Side effects are mostly mild and related to androgenic activity of DHEA in women and include increased sebum production, facial acne, and changes in hair status. Replacement consists of a single oral dose of 25-50 mg DHEA in the morning. However, not all investigators have found effects of DHEA on well-being, most likely because of small sample size and short duration of treatment. Thus, to fully explore the role of DHEA in the treatment of Al large trials for 12-24 months are still urgently needed. Until the results of such trials are available DHEA cannot be considered part of standard replacement in Al, but compassionate use of DHEA in individual patients with Al and impaired well-being may be justified. (c) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:268 / 273
页数:6
相关论文
共 52 条
[21]  
GURNELL EM, 2002, 84 ANN M END SOC SAN, P33
[22]  
HAHNER S, 2007, INPUB IMPAIRED SUBJE
[23]   No evidence for hepatic conversion of dehydroepiandrosterone (DHEA) sulfate to DHEA:: In vivo and in vitro studies [J].
Hammer, F ;
Subtil, S ;
Lux, P ;
Maser-Gluth, C ;
Stewart, PM ;
Allolio, B ;
Arlt, W .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (06) :3600-3605
[24]   Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial [J].
Hunt, PJ ;
Gurnell, EM ;
Huppert, FA ;
Richards, C ;
Prevost, AT ;
Wass, JAH ;
Herbert, J ;
Chatterjee, VKK .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (12) :4650-4656
[25]   Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women:: A placebo-controlled trial [J].
Johannsson, G ;
Burman, P ;
Wirén, L ;
Engstróm, BE ;
Nilsson, AG ;
Ottosson, M ;
Jonsson, B ;
Bengtsson, BÅ ;
Karlsson, FA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (05) :2046-2052
[26]   Dehydroepiandrosterone replacement in Addison's disease [J].
Kim, SS ;
Brody, KH .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2001, 97 (01) :96-97
[27]   INTRACRINOLOGY [J].
LABRIE, F .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1991, 78 (03) :C113-C118
[28]   Dehydroepiandrosterone sulfate is neuroprotective in a reversible spinal cord ischemia model -: Possible involvement of GABAA receptors [J].
Lapchak, PA ;
Chapman, DF ;
Nunez, SY ;
Zivin, JA .
STROKE, 2000, 31 (08) :1953-1956
[29]   Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism [J].
Libè, R ;
Barbetta, L ;
Dall'Asta, C ;
Salvaggio, F ;
Gala, C ;
Beck-Peccoz, P ;
Ambrosi, B .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2004, 27 (08) :736-741
[30]   Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Gαi2,3 [J].
Liu, DM ;
Dillon, JS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (24) :21379-21388